Tag: Motor fluctuations

Affecting nearly 1 million people in the United States, Parkinson's disease can cause debilitating motor fluctuations known as 'off' episodes. For many with mid- to late-stage disease, safinamide is used for management as an add-on treatment to levodopa to help smooth out these symptoms.

Globally, over 8.5 million people were living with Parkinson's disease (PD) in 2019 [1.5.7]. For many, treatment involves multiple drugs, raising the question: **Can you take pramipexole and levodopa together?** Yes, this combination is a cornerstone of modern PD management [1.4.1].

In the United States, nearly 90,000 people are diagnosed with Parkinson's disease each year [1.10]. For many, a key question becomes **what is Comtan prescribed for?** This medication serves as an adjunctive therapy to manage symptoms as the disease progresses.

Motor fluctuations emerge in approximately 40% of Parkinson's disease patients after 4-6 years. So, what is the drug Dhivy used for in managing these symptoms? Dhivy is a prescription medication designed to provide a flexible dosing option for patients experiencing these changes.

Patients with Parkinson's disease (PD) who have been on long-term levodopa therapy often face motor fluctuations and disabling "off" episodes as the medication's effect wears off. For these individuals, understanding what are the benefits of taking opicapone becomes crucial for optimizing treatment and improving their quality of life. Opicapone is a third-generation catechol-O-methyltransferase (COMT) inhibitor, which plays a key role in extending the availability of levodopa in the brain.

In a 2022 Phase III clinical trial, continuous Produodopa treatment led to a significant increase in daily 'on' time for people with advanced Parkinson's disease. **What is Produodopa?** It is an innovative, continuous-infusion therapy designed to manage severe motor fluctuations that are no longer adequately controlled by oral medications.

When it was introduced in the late 1960s, levodopa was hailed as a revolutionary treatment, unlocking movement for many patients who had been immobilized by the progressive disease. The question, **What is the miracle drug for Parkinson's?**, quickly centered on this powerful medication for its dramatic, if temporary, effects.

Approximately 90,000 Americans are diagnosed with Parkinson's disease each year [1.3.8]. For those with advanced stages, a treatment called Vyalev offers a new approach to managing symptoms. So, what is Vyalev and how does it work? [1.2.1, 1.2.2]

In February 2025, the U.S. Food and Drug Administration (FDA) approved Onapgo, the first infusion-based apomorphine therapy for advanced Parkinson's disease in the United States. This innovative treatment delivers a continuous infusion of medication via a wearable pump during waking hours.